ClinicalTrials.gg
CompletedNCT05896930Updated Jun 9, 2023

Study to Evaluate EBA, Safety and Tolerability of Carbapenems in Adults With Pulmonary Tuberculosis

A Phase 2 interventional study of Meropenem 6g IV over 6 hours and Ertapenem 1g IM in Pulmonary Tuberculosis, sponsored by TASK Applied Science. Completed at 1 site in South Africa. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-06-09.

Sponsored by TASK Applied Science · Phase 2, Interventional, and Other

How we know

From the registry’s dates

  • Registered 5 years 5 months after the study started (first participant enrolled Nov 2017, registered Apr 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
134
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 78 studies in Tuberculosis, Pulmonary with a site in South Africa — 10 open to participants now, 13 under way, 3 of them phase 3. Tuberculosis, Pulmonary · South Africa.

Enrollment
30th of 67
134 · median 122
Started
2017
with 6 others
Phase 2
49 of 78
8 open now
Registered
64th of 78
by date
Lead sponsor
6 of 78
TASK Applied Science

Among the 78 studies in Tuberculosis, Pulmonary with a site in South Africa, this one is the 30th largest by enrollment of the 67 interventional ones that give a count, is one of 7 that started in 2017, is one of 49 in phase 2, and was the 64th registered.

Tuberculosis, Pulmonary

320 studies on the registry are indexed under Tuberculosis, Pulmonary; 72 are open to participants now.

Browse Tuberculosis, Pulmonary studies →

Open to participants now

10 of the 78 studies in Tuberculosis, Pulmonary with a site in South Africa are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in South Africa have not opened yet or have stopped. Only those recruiting at a site in South Africa →

Who these studies take

Of the 47 Tuberculosis, Pulmonary studies recruiting now, 22 (47%) set no upper age limit and 21 (45%) stop at 75 or younger; 12 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies in Tuberculosis, Pulmonary with a site in South Africa, or all of them as a file.
02

Study summary

The goal of this single-center, open-labelled, clinical trial in two groups aims to proof that a specific group of antibiotics (carbapenems) can be used to treat pulmonary tuberculosis if it is combined with another antibiotic (amoxicillin/clavulanate). A total of 113 male or female participants (8 groups and 9 treatment regimens as group 8 was split into 2 groups of 4 participants receiving Rifafour e-275), aged between 18 and 65 years (inclusive), with newly diagnosed, smear-positive, pulmonary TB.

Read the detailed description

The overall objective of this study is to evaluate the 2-week bactericidal activity and pharmacokinetics of the following beta-lactam containing combinations with the aim to select the most active and implementable solution to be incorporated into a drug-resistant TB combination regimen:

  • Once or twice daily meropenem administered intravenously in combination with once or twice daily oral amoxicillin/clavulanic acid;
  • Once daily ertapenem administered intravenously and intramuscularly in combination with twice daily oral amoxicillin/clavulanic acid;
  • Twice daily oral amoxicillin/clavulanic acid;
  • Once daily rifampicin administered orally at highest currently established dosage of 35mg/kg in combination with twice daily oral amoxicillin/clavulanic acid.

A single-center, open-labeled, clinical trial in two groups. The treatments are:

Group 1:

  1. Meropenem 6g intravenously once daily; plus amoxicillin/CA 2 x 1000mg/62.5mg orally 12-hourly on days 1-14.
  2. Ertapenem 1g intramuscularly once daily; plus amoxicillin/CA 2 x 1000mg/62.5mg orally 12-hourly on days 1-14.

    Group 2:

  3. Meropenem 3g intravenously twice daily; plus amoxicillin/CA 2 x 1000mg/62.5mg orally 12-hourly on days 1-14.
  4. Ertapenem 1g intravenously once daily; plus amoxicillin/CA 2 x 1000mg/62.5mg orally 12-hourly on days 1-14.
  5. Amoxicillin/CA 2 x 1000mg/62.5mg orally 12-hourly on days 1-14.
  6. Rifampicin 35 mg/kg once daily; plus amoxicillin/CA 2 x 1000mg/62.5mg orally 12-hourly on days 1-14.
  7. Meropenem 6g OR meropenem 4g intravenously once daily; plus amoxicillin/CA 2 x 1000mg/62.5mg orally once daily on days 1-14.

A total of 4 participants per group will receive standard first line TB treatment as per the South African TB guidelines (Rifafour e-275) and is included as a control for the EBA quantitative mycobacteriology and to evaluate whether HRZE gives similar EBA results to that demonstrated in prior studies with this combination. The mycobacteriology laboratory will remain blinded until closure of the EBA results. Enrollment into group 1 will be completed before enrollment into group 2 will start. After completion of enrollment into group 1, there will be an interim analysis while enrollment into group 2 is ongoing.

03

Conditions studied

  • Pulmonary Tuberculosis

Keywords

  • EBA
  • Intravenous Meropenem
  • Newly Diagnosed
  • Smear-Positive
  • Rifampicin-Susceptible
  • Pulmonary Tuberculosis
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provide written, prior to all trial-related procedures including testing.
  2. Male or female, aged between 18 and 65 years, inclusive.
  3. Body weight (in light clothing and with no shoes) between 40 and 90 kg, inclusive.
  4. Newly diagnosed, previously untreated, rifampicin-susceptible pulmonary TB.
  5. A chest X-ray picture which in the opinion of the Investigator is consistent with TB.
  6. Sputum positive on direct microscopy for acid-fast bacilli on at least one sputum sample (at least 1+ on the IUATLD/WHO scale).
  7. Ability to produce an adequate volume of sputum as estimated from an overnight sputum collection sample (estimated 10 ml or more).
  8. Be of non- or using effective methods of , as defined below:

Non-childbearing potential:

  1. Participant - not heterosexually active or practicing sexual abstinence; or
  2. Female participant/sexual partner - bilateral oophorectomy, bilateral tubal ligation and/or hysterectomy or has been with a history of no menses for at least 12 consecutive months; or
  3. Male participant/sexual partner - vasectomised or has had a bilateral orchidectomy minimally three month prior to screening;

Effective birth control methods:

  1. Double barrier method which can include a male condom, diaphragm, cervical cap, or female condom (male and female condoms should not be used together); or
  2. Barrier method combined with hormone-based contraceptives or an intra-uterine device for the female partner; and are willing to continue practicing birth control methods throughout participation in the study until Visit 19 (day 28).

(Note: hormone-based contraception alone may not be reliable when taking IP; therefore, hormone-based contraceptives alone cannot be used by female participants to prevent pregnancy).

Exclusion criteria

Exclusion Criteria:

  1. Evidence of conditions or findings, other than the indication being studied, particularly epilepsy, that might compromise safety or the interpretation of trial endpoints, per discretion of the Investigator.
  2. Poor general condition where any delay in treatment cannot be tolerated per discretion of the Investigator.
  3. A history of TB less than 3 years ago.
  4. Clinically significant evidence of extrathoracic TB (miliary TB, abdominal TB, urogenital TB, osteoarthritic TB, TB meningitis), as judged by the Investigator.
  5. History of allergy to any of the trial IP/s or related substances i.e. β-lactams and penicillin, as confirmed by the clinical judgement of the Investigator.
  6. Known or suspected, current or history of within the past 2 years, alcohol or drug abuse, that is, in the opinion of the Investigator, sufficient to compromise the safety or cooperation of the participant.
  7. infected participants.
  8. Having participated in other clinical studies with agents within 8 weeks prior to trial start.
  9. Female participant who is pregnant, breast-feeding, or planning to conceive a child within the anticipated period of participating in the trial. Male participant planning to conceive a child within the anticipated period of participating in the trial.
  10. Subjects with diabetes (Type 1 or 2), point of care above 6.5, or random glucose over 11.1 mmol/L.
  11. to local anaesthesia of amide type.
  12. Treatment received with any drug active against MTB (including but not limited to isoniazid, ethambutol, amikacin, cycloserine, fluoroquinolones, rifabutin, rifampicin, streptomycin, kanamycin, para-aminosalicylic acid, rifapentine, pyrazinamide, thioacetazone, capreomycin, thioamides, metronidazole), or with medications such as TNF-alpha inhibitors or systemic or inhaled , within 2 weeks prior to screening
  13. Participants with the following toxicities at screening as defined by the enhanced CTCEA toxicity table

    1. creatinine grade 2 or greater (>1.5 times [ULN]);
    2. \<7.5 g/dL;
    3. grade 2 or greater (under 50x109 cells/L);
    4. serum potassium grade 2 or greater (\<3.0 mEq/L);
    5. (AST) grade 3 (≥3.0 x ULN) to be excluded;
    6. alanine aminotransferase (ALT) grade 3 (≥3.0 x ULN) to be excluded;
    7. grade 3
    8. INR grade 3
    9. Total white cell count grade 3
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 2
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
134 participants (actual)

Study arms

  • Experimental
    Group 1 Arm 1

    Meropenem 6g IV over 6 hours plus amoxicillin/CA

    Drug: Meropenem 6g IV over 6 hours · Drug: Amoxicillin/CA twice daily

  • Experimental
    Group 1 Arm 2

    Ertapenem 1g IM plus amoxicillin/CA

    Drug: Ertapenem 1g IM · Drug: Amoxicillin/CA twice daily

  • Experimental
    Group 2 Arm 1

    Meropenem 3g over 1 hour twice daily plus amoxicillin/CA

    Drug: Meropenem 3g IV · Drug: Amoxicillin/CA twice daily

  • Experimental
    Group 2 Arm 2

    Ertapenem 1g IV plus amoxicillin/CA

    Drug: Ertapenem 1g IV · Drug: Amoxicillin/CA twice daily

  • Experimental
    Group 2 Arm 3

    Amoxicillin; CA

    Drug: Amoxicillin/CA twice daily

  • Experimental
    Group 2 Arm 4

    Rifampicin 35mg/kg plus amoxicillin/CA

    Drug: Amoxicillin/CA twice daily · Drug: Rifampicin 35 mg/kg

  • Experimental
    Group 2 Arm 5

    Meropenem 6g or 4g IV over 60 minutes plus amoxicillin/CA

    Drug: Meropenem 6g IV over 60 minutes · Drug: Meropenem 4g IV · Drug: Amoxicillin/CA once daily

  • Active comparator
    Group 1

    Rifafour e-275

    Drug: Rifafour e-275

Interventions

06

What researchers measure

Primary outcomes

  1. Early bactericidal activity by change in logCFU over 14 days

    The EBACFU(0-14) as determined by the rate of change in logCFU (colony forming units) per ml sputum over the period Day 0 to Day 14 which will be summarised and described with a statistical model as an estimated average decrease per day for patients in each group.

    Time frame: 14 days

  2. Early bactericidal activity by change in time-to-positivity over 14 days

    The EBATTP(0-14) as determined by the percentage rate of change in TTP (time to positivity) per ml sputum over the period Day 0 to Day 14, which will be summarised and described with a statistical model as an estimated average increase per day for patients in each group.

    Time frame: 14 days

Secondary outcomes

  1. Early bactericidal activity by change in logCFU and TTP per ml over 0-2 days, 0-7 days, and 2-14 days

    Drug activity with CFU or TTP over different treatment periods such as 0-2 days, 0-7 days, and 2-14 days as indicated, for cross-comparison with other published data.

    Time frame: 0-2 days, 0-7 days, 2-14 days

07

Study locations

1 site
  • TASK Clinical Research Centre
    Cape Town, Western Cape 7530, South Africa
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2017 to primary completion in Jan 2021, 37 months.

Of 33 non-industry phase 2 interventional studies under Tuberculosis, Pulmonary, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 49. This study's 37 months is above that.

Counting every sponsor, half of 43 studies reached it within 30 months; a quarter within 21 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2023
First posted
Jun 9, 2023
StartActual
Nov 9, 2017
Primary completionActual
Jan 4, 2021
CompletionActual
Jan 4, 2021
Last update
Jun 9, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05896930
Lead sponsor
TASK Applied Science
Responsible party
Sponsor
First posted
Jun 9, 2023
Start date
Nov 9, 2017
Primary completion
Jan 4, 2021
Completion
Jan 4, 2021
Last update
Jun 9, 2023

Study contacts

Prof Andreas H Diacon, MD, PhD
principal investigator · TASK

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ertapenem · Meropenem · Rifampin

Start the discussion